Atopic Dermatitis

Panelists discuss how atopic dermatitis diagnosis in primary care relies on clinical features including pruritus, characteristic distribution, and chronic/relapsing course. Severity assessment involves examining extent, intensity, impact on quality of life, and response to previous treatments.

Investigators reported that roflumilast cream 0.05% significantly reduced AD severity as early as Week 1, with a notable effect on pruritus seen in as little as 24 hours.

Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.

The clearance enables Alphyn to initiate global phase 2b clinical trials, which are anticipated to begin in the first quarter of 2025.

Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

Your daily dose of the clinical news you may have missed.

With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.

An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.

Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.

There are no diagnostic criteria for topical steroid withdrawal but patients describe and discuss it on social media. Study authors tapped a deep source of information.

Findings showed that improved skin clearance and reduced anxiety and depression significantly influenced perceived patient benefit.

Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.